This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/q3-1-oct-to-31-dec-2023-annb-and-ypa-screening-kpi-data/antenatal-and-newborn-screening-kpi-data-q3-summary-factsheets-1-october-to-31-december-2023
This report should be read in conjunction with the full KPI data tables published each quarter.
1. Fetal anomaly screening
1.1
KPI FA2: coverage: fetal anomaly ultrasound
National performance of FA2 (see standard FASP-SO2) in quarter 2 2023 to 2024 was 98.7%. FA2 is collected 6 months (2 quarters) in arrears.
Quarter 2 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 2 2023 to 2024
130,485
132,169
98.7%
Region
Performance %
East of England
99.1%
London
98.1%
Midlands
98.9%
North East and Yorkshire
99.1%
North West
98.7%
South East
98.7%
South West
98.8%
England
98.7%
1.2
KPI FA3
There is no intention to publish FA3 (see standard FASP-S01) by individual maternity service.
1.3
KPI FA4: combined samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 3 2023 to 2024, national performance of FA4 for inadequate combined samples was 3.7%. FA4 is a KPI where a lower performance is better.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
4,059
108,412
3.7%
Region
Performance %
East of England
2.4%
London
1.5%
Midlands
4.3%
North East and Yorkshire
6.5%
North West
4.1%
South East
4.5%
South West
3.4%
England
3.7%
1.4
KPI FA4: quadruple samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 3 2023 to 2024, national performance of FA4 for inadequate quadruple samples was 7.9%. FA4 is a KPI where a lower performance is better.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
977
12,447
7.8%
Region
Performance %
East of England
4.7%
London
3.2%
Midlands
7.9%
North East and Yorkshire
13.1%
North West
6.3%
South East
13.1%
South West
13.6%
England
7.9%
2. Infectious diseases in pregnancy screening
2.1
KPI ID1: HIV coverage
National performance of ID1 (see standard IDPS-S01) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
150,994
151,262
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.8%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.7%
England
99.8%
2.2
KPI ID2: diagnosis/intervention: timely assessment of women with hepatitis B
National performance of ID2 (see standard IDPS-S06) in quarter 3 2023 to 2024 was 68.6%. The submission of data for ID2 has changed in 2023 to 2024 from maternity service self-reporting to the Integrated Screening Outcomes Surveillance Service (ISOSS) to improve consistency and accuracy of data returns. This has led to an expected reduction in performance as a result of more accurate data, and does not reflect a change in practice for screening providers.
ID2 is a small number KPI, therefore the data should be interpreted with caution.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
109
159
68.6%
Region
Performance %
East of England
81.2%
London
71.1%
Midlands
76.7%
North East and Yorkshire
69.6%
North West
50.0%
South East
66.7%
South West
50.0%
England
68.6%
2.3
KPI ID3: coverage: hepatitis B
National performance of ID3 (see standard IDPS-S02) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
150,987
151,253
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.8%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.7%
England
99.8%
2.4
KPI ID4: coverage: syphilis
National performance of ID4 (see standard IDPS-S03) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
150,985
151,256
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.8%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.7%
England
99.8%
3. Sickle cell and thalassaemia screening
3.1
KPI ST1: coverage: antenatal screening
National performance of ST1 (see standard SCT-S01) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
150,862
151,161
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.8%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.6%
England
99.8%
3.2
KPI ST2: test: timeliness of antenatal screening
National performance of ST2 (see standard SCT-S02) in quarter 3 2023 to 2024 was 61.5%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
93,887
152,543
61.5%
Region
Performance %
East of England
64.4%
London
57.9%
Midlands
55.8%
North East and Yorkshire
71.0%
North West
58.0%
South East
62.5%
South West
65.3%
England
61.5%
3.3
KPI ST3: test: completion of family origin questionnaire (FOQ)
National performance of ST3 (see standard SCT-S03) in quarter 3 2023 to 2024 was 97.9%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
149,091
152,319
97.9%
Region
Performance %
East of England
97.8%
London
99.7%
Midlands
96.6%
North East and Yorkshire
98.1%
North West
97.5%
South East
97.2%
South West
98.4%
England
97.9%
3.4
KPI ST4a: referral: timely offer of prenatal diagnosis (PND) to women at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4a (see standard SCT-S05) in quarter 3 2023 to 2024 was 44.9%. Thresholds have not yet been set for this KPI.
ST4a is a small number KPI, therefore the data should be interpreted with caution.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
207
461
44.9%
Region
Performance %
East of England
50.0%
London
48.9%
Midlands
35.3%
North East and Yorkshire
61.4%
North West
37.0%
South East
33.3%
South West
40.0%
England
44.9%
3.5
KPI ST4b: referral: timely offer of prenatal diagnosis (PND) to couples at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4b (see standard STC-S05) in quarter 3 2023 to 2024 was 65.6%. Thresholds have not yet been set for this KPI.
ST4b is a small number KPI, therefore the data should be interpreted with caution.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
206
314
65.6%
Region
Performance %
East of England
79.2%
London
72.0%
Midlands
66.2%
North East and Yorkshire
62.3%
North West
52.8%
South East
57.1%
South West
60.0%
England
65.6%
4. Newborn blood spot screening
4.1
KPI NB1: coverage of CCG responsibility at birth
National performance of NB1 (see standard NBS-S01a) in quarter 3 2023 to 2024 was 97.0%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
134,371
138,517
97.0%
Region
Performance %
East of England
99.7%
London
95.9%
Midlands
96.6%
North East and Yorkshire
97.3%
North West
96.3%
South East
97.6%
South West
96.4%
England
97.0%
4.2
KPI NB2: test: quality of the blood spot sample
National performance of NB2 (see standard NBS-S06) in quarter 3 2023 to 2024 was 2.6%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
3,536
136,979
2.6%
Region
Performance %
East of England
2.3%
London
2.2%
Midlands
2.5%
North East and Yorkshire
2.9%
North West
2.7%
South East
3.1%
South West
2.4%
England
2.6%
4.3
KPI NB4: coverage of movers in
National performance of NB4 (see standard NBS-S01b) in quarter 3 2023 to 2024 was 77.6%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
9,821
12,657
77.6%
Region
Performance %
East of England
86.4%
London
68.0%
Midlands
71.5%
North East and Yorkshire
85.9%
North West
83.0%
South East
81.9%
South West
77.5%
England
77.6%
5. Newborn hearing screening
5.1
KPI NH1: coverage
National performance of NH1 (see standard NHSP-S01) in quarter 3 2023 to 2024 was 98.9%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
146,555
148,111
98.9%
Region
Performance %
East of England
99.3%
London
98.5%
Midlands
99.2%
North East and Yorkshire
98.9%
North West
98.5%
South East
99.2%
South West
99.0%
England
98.9%
5.2
KPI NH2: diagnosis/intervention – time from screening outcome to attendance at an audiological assessment appointment
National performance of NH2 (see standard NHSP-S05) in quarter 3 2023 to 2024 was 90.6%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
2,336
2,578
90.6%
Region
Performance %
East of England
86.7%
London
93.8%
Midlands
91.0%
North East and Yorkshire
89.9%
North West
85.7%
South East
95.5%
South West
92.9%
England
90.6%
6. Newborn and infant physical examination screening
6.1
KPI NP1: coverage
National performance of NP1 (see standard NIPE-S01) in quarter 3 2023 to 2024 was 96.3%.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
138,421
143,740
96.3%
Region
Performance %
East of England
97.0%
London
96.1%
Midlands
96.2%
North East and Yorkshire
96.3%
North West
95.8%
South East
96.1%
South West
97.4%
England
96.3%
6.2
KPI NP3: diagnosis/intervention – timeliness of ultrasound scan of the hips for developmental dysplasia
NP3 (see standard NIPE-S03) was introduced in 2021 to 2022. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 3 2023 to 2024, national performance of NP3 was 74.1%.
